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Background
In transthyretin (TTR) cardiac amyloidosis, myocardial
deposition and accumulation of liver-derived TTR fibrils
results in heart failure and death. The hereditary form
of the disease is caused by mutations in the TTR gene
and presents as familial amyloidotic cardiomyopathy
(FAC), whereas senile systemic amyloidosis (SSA) is an
acquired disease caused by wild-type TTR. There are
currently no approved therapies available for ATTR car-
diac amyloidosis. Revusiran is a liver-directed subcuta-
neously administered investigational RNA interference
therapeutic comprised of a GalNAc-siRNA conjugate
targeting both mutant and wild-type TTR mRNA. A Ph
2 study of revusiran in 26 patients with ATTR cardiac
amyloidosis, in which revusiran was generally well toler-
ated and associated with > 85% sustained knockdown of
serum TTR, was recently completed. A Ph 2 open label
extension (OLE) of revusiran, available to all patients
who participated in the Ph 2 trial, was initiated in
November 2014.
Methods
The primary objective of the OLE is to evaluate the
long-term safety of 500 mg revusiran administered as 5
daily doses followed by weekly dosing for 2 years. Data
on adverse events, laboratory assessments and ECG is
collected. Secondary and tertiary objectives include serial
assessments of pharmacodynamics, clinical outcomes
including 6-Minute walk test, mortality, hospitalization,
cardiac magnetic resonance imaging, 99mTechnetium
scan, cardiac biomarkers and patient-reported QoL.
Results
Patients who completed the Ph 2 trial include 12
patients with SSA and 14 patients with FAC (7 T60A,
5 V122I, 2 other). At the beginning of the Ph 2 study
baseline data for these 26 patients included: mean age,
68 years; mean 6-minute walk distance, 408 meters;
mean NT-proBNP, 3435 pg/mL; troponin I and T 0.13
and 0.045 ng/mL, respectively. The majority of patients
had mild or moderate heart failure with NYHA class II
(81%) and III (12%). All patients presented with intra-
ventricular septal thickness (IVS) of > 15 mm (mean
IVS 19 mm).
Conclusions
As of June 8th 2015, 25 patients have been enrolled in
the OLE. Interim 6-month data on safety, PD and clini-
cal outcomes will be presented.
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